title: The breast cancer prevention trial: should women at risk take tamoxifen?
abstract: Tamoxifen is nonsteroidal antiestrogen originally developed in 1996 as a contraceptive. Recently, tamoxifen has been under study within the massive Breast Cancer Prevention Trial-but have we learned enough to recommend tamoxifen for breast cancer prevention? This article looks at the drug therapies, including tamoxifen, currently under development for fighting and preventing breast cancer.
authors.affiliation: Saint Anselm College in Manchester, NH, USA.
authors.forename: V A
authors.initials: VA
authors.lastname: McKeon
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D018849:Controlled Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018579:Patient Selection; D011247:Pregnancy; D011379:Prognosis; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000453:epidemiology; D018570:Risk Assessment; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects; D013924:Thrombophlebitis / Q000139:chemically induced / Q000453:epidemiology; D014481:United States
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen